{"id":388534,"date":"2023-12-18T14:34:52","date_gmt":"2023-12-18T19:34:52","guid":{"rendered":"https:\/\/platohealth.ai\/prime-medicine-mukherjees-myeloid-therapeutics-clash-over-genome-editing-deal\/"},"modified":"2023-12-18T20:31:57","modified_gmt":"2023-12-19T01:31:57","slug":"prime-medicine-mukherjees-myeloid-therapeutics-clash-over-genome-editing-deal","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/prime-medicine-mukherjees-myeloid-therapeutics-clash-over-genome-editing-deal\/","title":{"rendered":"Prime Medicine, Mukherjee\u2019s Myeloid Therapeutics clash over genome-editing deal","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

T<\/span><\/span>he closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new form of genome editing.<\/p>\n

Prime and Myeloid Therapeutics, a startup co-founded by Pulitzer Prize-winning writer and cancer biologist Siddhartha Mukherjee, have filed competing arbitration claims over a deal they signed in March 2022.<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

Prime, spun out of the lab of Broad Institute biochemist David Liu, was built on technology for making small insertions, deletions, and single-letter changes in DNA. In theory, prime editing allows researchers to tackle the vast majority of disease-causing mutations, and the first treatments are already being readied for clinical trials. But it\u2019s a poor fit in cases where hundreds or even thousands of different mutations in a long gene cause the same diseases, such as cystic fibrosis or Duchenne muscular dystrophy.<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n